Tildrakizumab is prescribed for:
- Moderate-to-severe plaque psoriasis
- Adults who are candidates for systemic therapy or phototherapy
- Dermatologic autoimmune conditions
Back to Medication Guide
Tildrakizumab
Generic Name: Tildrakizumab-asmn
Brand Names: Ilumya
Tildrakizumab is an IL-23 inhibitor biologic for moderate-to-severe plaque psoriasis.
DermatologicBiologic
What It's Used For
Side Effects
Common side effects:
- Upper respiratory infections
- Injection site reactions
- Diarrhea
Serious side effects:
- Serious infections
- Hypersensitivity reactions
Additional Information
What is Tildrakizumab?
Tildrakizumab is an IL-23 inhibitor that blocks the p19 subunit of IL-23.
Dosing
Administered at weeks 0 and 4, then every 12 weeks - one of the least frequent dosing schedules among biologics.
Efficacy
While highly effective, response rates may be slightly lower than some newer IL-23 inhibitors.
For more information, see MedlinePlus.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Ask Dr. Zimmer
Have questions about Tildrakizumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.